ATE471340T1 - Peptide der amylin familie, verfahren zu deren herstellung und verwendung - Google Patents
Peptide der amylin familie, verfahren zu deren herstellung und verwendungInfo
- Publication number
- ATE471340T1 ATE471340T1 AT05723040T AT05723040T ATE471340T1 AT E471340 T1 ATE471340 T1 AT E471340T1 AT 05723040 T AT05723040 T AT 05723040T AT 05723040 T AT05723040 T AT 05723040T AT E471340 T1 ATE471340 T1 AT E471340T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- production
- peptides
- amylin family
- amylin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/585—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54327504P | 2004-02-11 | 2004-02-11 | |
US55044704P | 2004-03-04 | 2004-03-04 | |
PCT/US2005/004631 WO2006083254A1 (en) | 2004-02-11 | 2005-02-11 | Amylin family peptides and methods for making and using them |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE471340T1 true ATE471340T1 (de) | 2010-07-15 |
Family
ID=34963236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05723040T ATE471340T1 (de) | 2004-02-11 | 2005-02-11 | Peptide der amylin familie, verfahren zu deren herstellung und verwendung |
Country Status (14)
Country | Link |
---|---|
US (2) | US8114958B2 (de) |
EP (2) | EP2233497A3 (de) |
JP (1) | JP2008500281A (de) |
KR (1) | KR101196122B1 (de) |
AT (1) | ATE471340T1 (de) |
AU (2) | AU2005320351B2 (de) |
BR (1) | BRPI0507623A (de) |
CA (1) | CA2556226A1 (de) |
DE (1) | DE602005021858D1 (de) |
ES (1) | ES2345113T3 (de) |
IL (2) | IL177230A0 (de) |
NZ (2) | NZ549332A (de) |
RU (1) | RU2385878C2 (de) |
WO (1) | WO2006083254A1 (de) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0507623A (pt) * | 2004-02-11 | 2007-07-03 | Amylin Pharmaceuticals Inc | peptìdeos da famìlia da amilina e métodos para prepará-los e empregá-los |
US8076288B2 (en) | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
EP2286840A3 (de) | 2004-11-01 | 2013-09-04 | Amylin Pharmaceuticals, LLC | Behandlung von Fettleibigkeit und von verwandten Krankheiten |
US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
ES2330671T3 (es) | 2005-03-31 | 2009-12-14 | Amylin Pharmaceuticals, Inc. | Amilina y agonistas de amilina para el tratamiento de enfermedades y trastornos psiquiatricos. |
WO2008097536A2 (en) | 2007-02-05 | 2008-08-14 | Amylin Pharmaceuticals, Inc. | Compositions and methods for treating psychiatric diseases and disorders |
US20110152183A1 (en) * | 2008-06-25 | 2011-06-23 | Novo Nordisk A/S | Derivatised hybrid peptides of amylin and salmon calcitonin |
US20110201022A1 (en) * | 2008-07-30 | 2011-08-18 | Biomarin Pharmaceutical Inc. | Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase |
BRPI1006943A2 (pt) * | 2009-01-22 | 2021-06-15 | Unigene Laboratories Inc. | peptídeo, composição farmacêutica que compreende o peptídeo e método para supressão do apetite, prevenção ou tratamento de uma condição de sobrepeso ou obesidade, ou para tratar diabetes |
NZ595021A (en) * | 2009-03-12 | 2013-04-26 | Nordic Bioscience As | Treatment of diabetes and metabolic syndrome with enteral formulations of calcitonin peptides or calcitonin receptor agonists |
WO2010107874A2 (en) | 2009-03-17 | 2010-09-23 | Amylin Pharmaceuticals, Inc. | Methods for affecting body composition using amylin agonists |
WO2010118384A2 (en) | 2009-04-10 | 2010-10-14 | Amylin Pharmaceuticals, Inc. | Amylin agonist compounds for estrogen-deficient mammals |
MX2012005912A (es) | 2009-11-23 | 2012-10-05 | Amylin Pharmaceuticals Inc | Conjugado de polipeptido. |
GB201001333D0 (en) | 2010-01-27 | 2010-03-17 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
CA2782444C (en) | 2010-02-04 | 2018-10-23 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof |
PT2621519T (pt) | 2010-09-28 | 2017-10-04 | Aegerion Pharmaceuticals Inc | Polipéptido de fusão de leptina-abd com duração de ação melhorada |
CN106986940A (zh) | 2010-09-28 | 2017-07-28 | 艾米琳制药有限责任公司 | 具有增强的作用持续时间的工程化多肽 |
CN103458916B (zh) | 2011-04-07 | 2016-08-10 | 小利兰·斯坦福大学托管委员会 | 长效肽类似物 |
US20140221287A1 (en) * | 2011-05-25 | 2014-08-07 | Astrazeneca Pharmaceuticals Lp | Amylin Peptides and Derivatives and Uses Thereof |
WO2012160212A1 (en) | 2011-05-25 | 2012-11-29 | Camurus Ab | Peptide controlled-release formulations |
US20140221282A1 (en) | 2011-05-25 | 2014-08-07 | Astrazeneca Pharmaceuticals Lp | Long duration dual hormone conjugates |
JP6006309B2 (ja) | 2011-07-08 | 2016-10-12 | アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals,Llc | 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド |
DK2729160T3 (da) | 2011-07-08 | 2019-07-01 | Aegerion Pharmaceuticals Inc | Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet |
WO2013059336A1 (en) * | 2011-10-18 | 2013-04-25 | Amylin Pharmaceuticals, Llc | Amylin-calcitonin chimeric peptides conjugated to duration enchancing moieties |
MX351092B (es) | 2011-11-02 | 2017-10-02 | Keybioscience Ag | Analogos peptidicos para tratar enfermedades y trastornos. |
US9533022B2 (en) | 2011-11-02 | 2017-01-03 | KeyBioscience A/S | Peptide analogs for treating diseases and disorders |
CA2861392C (en) | 2012-01-26 | 2021-08-17 | Christopher J. Soares | Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use |
WO2013151729A1 (en) | 2012-04-03 | 2013-10-10 | Trustees Of Boston University | Compositions, methods and assays comprising amylin or amlyin analogs for abeta-peptide mediated disorders |
US8575091B1 (en) | 2012-04-19 | 2013-11-05 | Novo Nordisk A/S | Amylin analogues and pharmaceutical compositions thereof |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
CN104870009B (zh) | 2012-12-21 | 2021-05-18 | 赛诺菲 | 官能化的毒蜥外泌肽-4衍生物 |
BR102013017626A2 (pt) * | 2013-06-14 | 2015-02-10 | Univ Rio De Janeiro | Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças. |
JP6538682B2 (ja) * | 2013-07-30 | 2019-07-03 | ソアレス クリストファー ジェイ. | Cgrpアゴニストペプチド |
AR097701A1 (es) * | 2013-09-19 | 2016-04-13 | Zealand Pharma As | Análogos de amilina |
EP3080152A1 (de) | 2013-12-13 | 2016-10-19 | Sanofi | Nicht-acylierte exendin-4-peptidanaloga |
EP3080154B1 (de) | 2013-12-13 | 2018-02-07 | Sanofi | Duale glp-1/gip-rezeptoragonisten |
EP3080149A1 (de) | 2013-12-13 | 2016-10-19 | Sanofi | Duale glp-1-/glucagon-rezeptoragonisten |
TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
MX2017011182A (es) | 2015-03-18 | 2018-06-06 | Zealand Pharma As | Analogos de amilina. |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
BR102015031283A2 (pt) * | 2015-12-14 | 2018-09-18 | Univ Rio De Janeiro | Bioconjugado de amilina humana ou de análogos de amilinanão agregantes, composição, métodos para a preparação deuma composição, para o tratamento de uma doença oucondição e para estabilizar um composto amilino-mimético, e,medicamento |
EP3400237A4 (de) | 2016-01-04 | 2020-03-04 | Adepthera LLC | Peptidanaloga |
EP3416676B1 (de) | 2016-02-09 | 2021-12-08 | Adepthera LLC | Dosierung und verwendung von lang wirkenden clr/ramp-agonisten |
JP7123932B2 (ja) | 2016-09-02 | 2022-08-23 | クリストファー ジェイ. ソアレス | 神経保護及び神経疾患におけるcgrp受容体アンタゴニストの使用 |
US10071140B2 (en) * | 2016-09-09 | 2018-09-11 | Zealand Pharma A/S | Amylin analogues |
US20190153059A1 (en) | 2017-06-30 | 2019-05-23 | Adepthera Llc | Peptide analogs |
PE20211202A1 (es) | 2017-08-24 | 2021-07-05 | Novo Nordisk As | Composiciones de glp-1 y sus usos |
JP2022549216A (ja) | 2019-09-23 | 2022-11-24 | ディーディーエス リサーチ インク. | 浸透促進剤を含有する脂質ベシクル組成物 |
WO2021144476A1 (en) | 2020-02-18 | 2021-07-22 | Novo Nordisk A/S | Pharmaceutical formulations |
BR112023019249A2 (pt) * | 2021-03-24 | 2023-12-12 | Glo Pharma Inc | Peptídeos e métodos para reduzir a pigmentação da pele |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
GB8720115D0 (en) * | 1987-08-26 | 1987-09-30 | Cooper G J S | Treatment of diabetes mellitus |
GB8709871D0 (en) | 1987-04-27 | 1987-06-03 | Turner R C | Peptides |
JP2796388B2 (ja) | 1988-05-13 | 1998-09-10 | アムジエン・インコーポレーテツド | G−csfの精製方法 |
US5264372A (en) | 1991-03-15 | 1993-11-23 | Amylin Pharmaceuticals, Inc. | Receptor-based screening methods for amylin agonists and antagonists |
HU222249B1 (hu) * | 1991-03-08 | 2003-05-28 | Amylin Pharmaceuticals Inc. | Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására |
US5580953A (en) * | 1991-08-14 | 1996-12-03 | Amylin Pharmaceuticals, Inc. | Amylin antagonist peptides and uses therefor |
US5912015A (en) * | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
JPH06256210A (ja) * | 1993-03-10 | 1994-09-13 | Hoechst Japan Ltd | 骨関連転写制御因子様タンパク質およびその製造法 |
JPH07509008A (ja) | 1993-05-12 | 1995-10-05 | ユニバーシティ・オブ・シンシナティ | アミリン・アンタゴニストおよびアゴニスト |
KR100429966B1 (ko) * | 1993-09-07 | 2004-05-04 | 아밀린 파마슈티칼스, 인크. | 위장 운동성 조절을 위한 제약 조성물 |
US5766627A (en) * | 1993-11-16 | 1998-06-16 | Depotech | Multivescular liposomes with controlled release of encapsulated biologically active substances |
US5739106A (en) * | 1995-06-07 | 1998-04-14 | Rink; Timothy J. | Appetite regulating compositions |
US6143718A (en) * | 1995-06-07 | 2000-11-07 | Amylin Pharmaceuticals, Inc. | Treatment of Type II diabetes mellutis with amylin agonists |
US5686511A (en) | 1996-06-28 | 1997-11-11 | The Valspar Corporation | Esterifying epoxy resin with carboxyl polymer and quenching |
US5677279A (en) | 1996-12-16 | 1997-10-14 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating pain with amylin or agonists thereof |
DE122007000044I2 (de) | 1997-01-07 | 2011-05-05 | Amylin Pharmaceuticals Inc | Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme |
US7312196B2 (en) * | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
US6410511B2 (en) | 1997-01-08 | 2002-06-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
US7101853B2 (en) | 1997-05-06 | 2006-09-05 | Amylin Pharmaceuticals, Inc. | Method for treating or preventing gastritis using amylin or amylin agonists |
US20040022807A1 (en) * | 1998-06-05 | 2004-02-05 | Duft Bradford J | Methods for treating obesity |
WO1999007404A1 (en) | 1997-08-08 | 1999-02-18 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist compounds |
US7157555B1 (en) | 1997-08-08 | 2007-01-02 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
ATE381939T1 (de) | 1997-11-14 | 2008-01-15 | Amylin Pharmaceuticals Inc | Neuartige exendin agonisten |
ATE383867T1 (de) | 1997-11-14 | 2008-02-15 | Amylin Pharmaceuticals Inc | Neuartige exendin agonisten |
US7220721B1 (en) | 1997-11-14 | 2007-05-22 | Amylin Pharmaceuticals, Inc. | Exendin agonist peptides |
US6936584B1 (en) * | 1998-02-13 | 2005-08-30 | Amylin Pharmaceuticals, Inc. | Mixed amylin activity compounds |
EP1053001B1 (de) * | 1998-02-13 | 2010-12-15 | Amylin Pharmaceuticals, Inc. | Neue verbindungen mit gemischter amylin aktivität |
US6087334A (en) * | 1998-08-21 | 2000-07-11 | Amylin Pharmaceuticals, Inc. | Anti-diabetic peptides |
US6194006B1 (en) * | 1998-12-30 | 2001-02-27 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of microparticles having a selected release profile |
US6458387B1 (en) * | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
US6264987B1 (en) * | 2000-05-19 | 2001-07-24 | Alkermes Controlled Therapeutics Inc. Ii | Method for preparing microparticles having a selected polymer molecular weight |
US6296842B1 (en) * | 2000-08-10 | 2001-10-02 | Alkermes Controlled Therapeutics, Inc. | Process for the preparation of polymer-based sustained release compositions |
US20030026182A1 (en) * | 2001-08-06 | 2003-02-06 | Fischer Michael C. | Method and system for write clock synchronization in a data storage system |
US8008255B2 (en) * | 2003-05-30 | 2011-08-30 | Amylin Pharmaceuticals, Inc. | Methods and compositions for enhanced transmucosal delivery of peptides and proteins |
BRPI0507623A (pt) * | 2004-02-11 | 2007-07-03 | Amylin Pharmaceuticals Inc | peptìdeos da famìlia da amilina e métodos para prepará-los e empregá-los |
NZ548978A (en) | 2004-02-11 | 2009-10-30 | Amylin Pharmaceuticals Inc | Hybrid polypeptides with selectable properties |
EP2335715A3 (de) | 2004-02-11 | 2013-12-18 | Amylin Pharmaceuticals, LLC | Pankreas-polypeptidfamilienmotive und diese enthaltende polypeptide |
US7399744B2 (en) * | 2004-03-04 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Methods for affecting body composition |
NZ555533A (en) | 2004-12-13 | 2010-03-26 | Amylin Pharmaceuticals Inc | Pancreatic polypeptide family motifs, polypeptides and methods comprising the same |
ES2330671T3 (es) * | 2005-03-31 | 2009-12-14 | Amylin Pharmaceuticals, Inc. | Amilina y agonistas de amilina para el tratamiento de enfermedades y trastornos psiquiatricos. |
-
2005
- 2005-02-11 BR BRPI0507623-4A patent/BRPI0507623A/pt not_active IP Right Cessation
- 2005-02-11 AT AT05723040T patent/ATE471340T1/de not_active IP Right Cessation
- 2005-02-11 RU RU2006132293/13A patent/RU2385878C2/ru not_active IP Right Cessation
- 2005-02-11 NZ NZ549332A patent/NZ549332A/en not_active IP Right Cessation
- 2005-02-11 DE DE602005021858T patent/DE602005021858D1/de active Active
- 2005-02-11 AU AU2005320351A patent/AU2005320351B2/en not_active Ceased
- 2005-02-11 ES ES05723040T patent/ES2345113T3/es active Active
- 2005-02-11 US US10/589,054 patent/US8114958B2/en not_active Expired - Fee Related
- 2005-02-11 NZ NZ571824A patent/NZ571824A/en not_active IP Right Cessation
- 2005-02-11 CA CA002556226A patent/CA2556226A1/en not_active Abandoned
- 2005-02-11 WO PCT/US2005/004631 patent/WO2006083254A1/en active Application Filing
- 2005-02-11 JP JP2007501804A patent/JP2008500281A/ja active Pending
- 2005-02-11 EP EP10006105A patent/EP2233497A3/de not_active Withdrawn
- 2005-02-11 EP EP05723040A patent/EP1716172B1/de active Active
-
2006
- 2006-08-02 IL IL177230A patent/IL177230A0/en unknown
- 2006-09-08 KR KR1020067018379A patent/KR101196122B1/ko not_active IP Right Cessation
-
2009
- 2009-12-17 IL IL202795A patent/IL202795A0/en unknown
-
2010
- 2010-08-20 AU AU2010212468A patent/AU2010212468A1/en not_active Ceased
-
2012
- 2012-02-01 US US13/364,250 patent/US8598120B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2556226A1 (en) | 2006-08-10 |
EP2233497A3 (de) | 2011-01-12 |
BRPI0507623A (pt) | 2007-07-03 |
RU2006132293A (ru) | 2008-03-20 |
US20120196796A1 (en) | 2012-08-02 |
KR101196122B1 (ko) | 2012-12-18 |
KR20070008589A (ko) | 2007-01-17 |
US20080274952A1 (en) | 2008-11-06 |
US8114958B2 (en) | 2012-02-14 |
IL202795A0 (en) | 2011-07-31 |
NZ571824A (en) | 2010-04-30 |
AU2005320351A8 (en) | 2008-12-18 |
EP1716172B1 (de) | 2010-06-16 |
AU2005320351B2 (en) | 2010-06-03 |
IL177230A0 (en) | 2006-12-10 |
NZ549332A (en) | 2008-11-28 |
AU2010212468A1 (en) | 2010-09-09 |
RU2385878C2 (ru) | 2010-04-10 |
JP2008500281A (ja) | 2008-01-10 |
AU2005320351A1 (en) | 2006-08-31 |
EP2233497A2 (de) | 2010-09-29 |
EP1716172A1 (de) | 2006-11-02 |
US8598120B2 (en) | 2013-12-03 |
DE602005021858D1 (de) | 2010-07-29 |
ES2345113T3 (es) | 2010-09-15 |
WO2006083254A1 (en) | 2006-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE471340T1 (de) | Peptide der amylin familie, verfahren zu deren herstellung und verwendung | |
WO2006042242A3 (en) | Amylin family polypeptide- 6 (afp- 6) analogs and methods of making and using them | |
WO2007022070A3 (en) | Modified fc molecules | |
HK1205193A1 (en) | Recombinant n-glycosylated proteins from procaryotic cells n- | |
BRPI0519766A2 (pt) | proteases Ácidas féngicas | |
ATE462000T1 (de) | Verfahren zur herstellung von l-arginin, l- ornithin oder l-citrullin | |
WO2007021494A3 (en) | Albumin fusion proteins | |
WO2005077042A3 (en) | Albumin fusion proteins | |
WO2008033413A3 (en) | Albumin fusion proteins | |
WO2007146038A3 (en) | Albumin fusion proteins | |
DE602004027723D1 (de) | Varianten von beta-glukosidasen | |
WO2005003296A3 (en) | Albumin fusion proteins | |
WO2009011855A3 (en) | Selection of nucleic acid-based sensor domains within nucleic acid switch platform | |
WO2009004315A8 (en) | Isolated peptides and uses thereof | |
DE502006006865D1 (de) | Neue dehydrogenasen, deren derivate und ein verfahren zur herstellung von optisch aktiven alkanolen | |
WO2006113475A3 (en) | Methods and compositions to modulate adhesion and stress tolerance in bacteria | |
WO2008005527A3 (en) | Glucagon-like peptides and uses thereof | |
ATE533837T1 (de) | Microginin-produzierende proteine und nukleinsäuren, einen microginin gen-cluster kodierend, sowie methoden zur herstellung von microgininen | |
ATE532502T1 (de) | Kosmetische zusammensetzung für das haar | |
WO2003040290A3 (de) | Gene aus corynebacterium glutamicum die fuer homeostase- und adaptions-proteine codieren | |
WO2007071578A3 (de) | Verfahren zur herstellung von 5 -norbornen-2-carbonsäure aus 5-norbornen-2-carbonitril unter verwendung einer arylacetonitrilase | |
WO2005097831A3 (en) | Uses of isolated binding members capable of binding specifically to secretagogues | |
WO2012144799A3 (ko) | 활성 폴리펩타이드의 결합 친화력 및 결합 특이성을 증강시키는 단백질 골격 모듈 | |
WO2005097830A3 (en) | Uses of isolated binding members capable of reducing the biological activity of secretagogue compounds | |
ATE556135T1 (de) | Neues protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |